MOTOFEN HALF-STRENGTH Drug Patent Profile

When do Motofen Half-strength patents expire, and what generic alternatives are available?

Motofen Half-strength is a drug marketed by Legacy Pharma and is included in one NDA.

The generic ingredient in MOTOFEN HALF-STRENGTH is atropine sulfate; difenoxin hydrochloride. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atropine sulfate; difenoxin hydrochloride profile page.

Summary for MOTOFEN HALF-STRENGTH

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MOTOFEN HALF-STRENGTH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma	MOTOFEN HALF-STRENGTH	atropine sulfate; difenoxin hydrochloride	TABLET;ORAL	017744-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for MOTOFEN HALF-STRENGTH

See the table below for patents covering MOTOFEN HALF-STRENGTH around the world.

Country	Patent Number	Title	Estimated Expiration
France	2022531
United Kingdom	1234359
Switzerland	517742	Procédé pour la préparation d'un acide isonipécotique substitué
Yugoslavia	34188
Poland	80327
Luxembourg	59733
Netherlands	6916611

Investment Scenario and Fundamentals Analysis for Motofen Half-Strength

Last updated: February 20, 2026

What Is Motofen Half-Strength?

Motofen Half-Strength is a formulation of difenoxin and atropine used primarily to treat diarrhea. It is a lower-dose version of Motofen, intended to reduce the potential for abuse and side effects associated with higher doses of the drug. The medication combines 0.5 mg of difenoxin with 0.025 mg of atropine per tablet, aiming to balance efficacy with safety.

Market Overview

The global antidiarrheal agents market, including formulations like Motofen, is driven by infectious diarrhea prevalence, opioid-receptor activity, and shifts toward combination therapies. The market size was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 4% through 2027 [1].

Key Competitors

• Loperamide (Imodium)
• Diphenoxylate combined with atropine (Lomotil)
• Motofen (difenoxin/atropine)
• New entrants focusing on non-opioid therapies

Motofen’s niche lies in specific patient groups where opioid-based therapies are contraindicated or poorly tolerated.

Patent Status and Regulatory Environment

Patent Status

• Motofen’s patent protection expired in several markets by 2015.
• No current patents protect the formulation as of 2023, enabling generic development.

Regulatory Pathways

• Approved by the FDA since 1981 under NDA 018693.
• Generic versions have entered multiple markets post-patent expiry.
• Regulatory hurdles focus on demonstrating bioequivalence and safety, common for generic drugs.

Clinical and Safety Fundamentals

Efficacy

• Effective in controlling diarrhea symptoms.
• Its opioid-like mechanism suppresses intestinal motility.
• Lower doses (half-strength) maintain efficacy while reducing side effects.

Safety Profile

• Atropine mitigates abuse potential but introduces anticholinergic side effects.
• Side effects include dry mouth, blurred vision, constipation, and urinary retention.
• Risk of toxicity, especially in overdose, remains low but present.

Marketed Formulations

• Available as over-the-counter and prescription medications.
• Half-strength formulations available in select markets, primarily as prescription versions.

Investment Considerations

Strengths

• Established safety and efficacy profile supported by decades of use.
• Patent expiration reduces barriers to entry for generics.
• Growing demand for effective, lower-toxicity antidiarrheal agents.

Weaknesses

• Market dominance of non-opioid drugs like loperamide.
• Regulatory uncertainties in emerging markets.
• Side effect profile limits wider acceptance in certain patient segments.

Opportunities

• Potential for reformulation as a non-opioid treatment.
• Expansion into new geographical markets with unmet needs.
• Development of combination therapies targeting specific patient demographics.

Threats

• Price erosion from generics.
• Modern non-opioid therapies under development.
• Regulatory restrictions on opioids and related drugs for diarrhea.

Financial Outlook

• Current annual sales in the US estimated at USD 50-80 million.
• Average wholesale price (AWP) for Motofen is approximately USD 5–7 per tablet.
• Market growth driven by healthcare access and aging populations.

Regulatory and Commercial Strategy

• Focus on differential positioning emphasizing safety, especially in vulnerable populations.
• Investment in clinical data to support repositioning or new formulation development.
• Partnership with generic manufacturers to reduce development costs and accelerate market entry.

Key Takeaways

• Motofen Half-Strength operates in a mature but still relevant segment of the antidiarrheal market.
• Patent expiration and generic availability increase market competition, putting pressure on prices.
• Safety profile favors use in specific patient groups, but side effects limit broader adoption.
• Market growth hinges on expanding geographic reach and positioning as a safer alternative.
• Regulatory pathways are straightforward for generics but require attention to country-specific policies.

FAQs

1. What is the main therapeutic advantage of Motofen Half-Strength?
   It offers effective diarrhea control with a lower dose of difenoxin, reducing abuse potential and side effects compared to higher-dose formulations.

2. How does the patent status affect investment potential?
   Expired patents allow for generic competition, potentially lowering prices but increasing market share for new entrants.

3. What are the main safety concerns associated with Motofen?
   Anticholinergic side effects include dry mouth, constipation, and urinary retention; overdose risks are minimal but present.

4. Are there significant regulatory hurdles for launching generic versions?
   No, provided bioequivalence and safety data are submitted, especially in markets with established regulatory pathways.

5. What market trends could impact Motofen's future sales?
   Competition from non-opioid therapies, regulatory restrictions on opioids, and increases in gastrointestinal health awareness influence the market trajectory.

References

[1] GlobalData. (2022). Antidiarrheal agents market report. Retrieved from https://www.globaldata.com/